Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder

First Posted Date
2013-02-22
Last Posted Date
2018-04-30
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
38
Registration Number
NCT01797575
Locations
🇺🇸

UT Center of Excellence on Mood Disorders, Houston, Texas, United States

Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke

First Posted Date
2013-02-13
Last Posted Date
2014-06-04
Lead Sponsor
Dexa Medica Group
Target Recruit Count
126
Registration Number
NCT01790997
Locations
🇮🇩

Stroke Unit, Department of Neurology, Faculty of Medicine, Gadjah Mada University, dr. Sardjito Hospital, Yogyakarta, Jogjakarta, Indonesia

Physiological Effects of Altering Cancer-related Inflammation

Not Applicable
Conditions
Interventions
First Posted Date
2013-02-07
Last Posted Date
2013-02-07
Lead Sponsor
NHS Greater Glasgow and Clyde
Target Recruit Count
60
Registration Number
NCT01786200
Locations
🇬🇧

Glasgow Royal Infirmary - Walton Building, Glasgow, United Kingdom

ASpirin for Patients With SEPsis and SeptIc Shock

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2013-02-05
Last Posted Date
2023-07-13
Lead Sponsor
Federal University of São Paulo
Target Recruit Count
167
Registration Number
NCT01784159
Locations
🇧🇷

Hospital São Paulo, São Paulo, Brazil

Effect of EECP on Anterior Ischemic Optic Neuropathy

First Posted Date
2013-01-15
Last Posted Date
2017-03-31
Lead Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Target Recruit Count
40
Registration Number
NCT01768260
Locations
🇨🇳

The First Affiliated Hospital of Sun Yat- sen University, Guangzhou, Guangdong, China

Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-01-15
Last Posted Date
2019-04-19
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
48
Registration Number
NCT01768637
Locations
🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

Enoxaparin Versus Aspirin in Patients With Cancer and Stroke

First Posted Date
2013-01-09
Last Posted Date
2020-08-14
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
20
Registration Number
NCT01763606
Locations
🇺🇸

New York Presbyterian Hospital, New York, New York, United States

🇺🇸

Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering West Harrison, Harrison, New York, United States

and more 4 locations

Phase I Methodology Study to Validate the Cantharidin Blister Model in Healthy Volunteers

First Posted Date
2013-01-08
Last Posted Date
2017-06-28
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
40
Registration Number
NCT01762787
Locations
🇬🇧

GSK Investigational Site, Cambridge, United Kingdom

The Carotid and Middle Cerebral Artery Occlusion Surgery Study

First Posted Date
2013-01-01
Last Posted Date
2021-11-12
Lead Sponsor
Xuanwu Hospital, Beijing
Target Recruit Count
330
Registration Number
NCT01758614
Locations
🇨🇳

Department of neurosurgery, Xuanwu hospital, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath